Abstract
Alzheimer's disease (AD) is characterized by the transition of amyloid-β (Aβ) monomers into toxic oligomers and plaques. Given that Aβ abnormality typically precedes the development of clinical symptoms, an agent capable of disaggregating existing Aβ aggregates may be advantageous. Here we report that a small molecule, 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS), binds to Aβ aggregates and converts them into monomers. The oral administration of EPPS substantially reduces hippocampus-dependent behavioural deficits, brain Aβ oligomer and plaque deposits, glial 3-aminobutyric acid (GABA) release and brain inflammation in an Aβ-overexpressing, APP/PS1 transgenic mouse model when initiated after the development of severe AD-like phenotypes. The ability of EPPS to rescue Aβ aggregation and behavioural deficits provides strong support for the view that the accumulation of Aβ is an important mechanism underlying AD.
| Original language | English |
|---|---|
| Article number | 8997 |
| Journal | Nature communications |
| Volume | 6 |
| DOIs | |
| Publication status | Published - 2015 Dec 8 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Chemistry(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Physics and Astronomy(all)
Cite this
}
EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques. / Kim, Hye Yun; Kim, Hyunjin Vincent; Jo, Seonmi; Lee, C. Justin; Choi, Seon Young; Kim, Dong Jin; Kim, YoungSoo.
In: Nature communications, Vol. 6, 8997, 08.12.2015.Research output: Contribution to journal › Article
TY - JOUR
T1 - EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques
AU - Kim, Hye Yun
AU - Kim, Hyunjin Vincent
AU - Jo, Seonmi
AU - Lee, C. Justin
AU - Choi, Seon Young
AU - Kim, Dong Jin
AU - Kim, YoungSoo
PY - 2015/12/8
Y1 - 2015/12/8
N2 - Alzheimer's disease (AD) is characterized by the transition of amyloid-β (Aβ) monomers into toxic oligomers and plaques. Given that Aβ abnormality typically precedes the development of clinical symptoms, an agent capable of disaggregating existing Aβ aggregates may be advantageous. Here we report that a small molecule, 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS), binds to Aβ aggregates and converts them into monomers. The oral administration of EPPS substantially reduces hippocampus-dependent behavioural deficits, brain Aβ oligomer and plaque deposits, glial 3-aminobutyric acid (GABA) release and brain inflammation in an Aβ-overexpressing, APP/PS1 transgenic mouse model when initiated after the development of severe AD-like phenotypes. The ability of EPPS to rescue Aβ aggregation and behavioural deficits provides strong support for the view that the accumulation of Aβ is an important mechanism underlying AD.
AB - Alzheimer's disease (AD) is characterized by the transition of amyloid-β (Aβ) monomers into toxic oligomers and plaques. Given that Aβ abnormality typically precedes the development of clinical symptoms, an agent capable of disaggregating existing Aβ aggregates may be advantageous. Here we report that a small molecule, 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS), binds to Aβ aggregates and converts them into monomers. The oral administration of EPPS substantially reduces hippocampus-dependent behavioural deficits, brain Aβ oligomer and plaque deposits, glial 3-aminobutyric acid (GABA) release and brain inflammation in an Aβ-overexpressing, APP/PS1 transgenic mouse model when initiated after the development of severe AD-like phenotypes. The ability of EPPS to rescue Aβ aggregation and behavioural deficits provides strong support for the view that the accumulation of Aβ is an important mechanism underlying AD.
UR - http://www.scopus.com/inward/record.url?scp=84949599389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949599389&partnerID=8YFLogxK
U2 - 10.1038/ncomms9997
DO - 10.1038/ncomms9997
M3 - Article
C2 - 26646366
AN - SCOPUS:84949599389
VL - 6
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
M1 - 8997
ER -